Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Inv. presentation
Capstone Therapeutics Corp. (CAPS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/26/2019 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I...
Docs: "Certificate of Amendment to the Restated Certificate of Incorporation of Capstone Therapeutics Corp",
"Contingent Value Rights Agreement",
"Third Amendment to the Securities Purchase, Loan and Securities Agreement"
03/19/2019 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Second Amendment to Securities Purchase, Loan and Security Agreement dated March 15, 2019, by and between Capstone Therapeutics, Corp. and BP Peptides, LLC"
05/07/2018 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "License Agreement dated May 2, 2018, by and between LipimetiX Development, Inc. and ANJI Pharmaceuticals Inc",
"LipimetiX Development Announces Sub-License of Apo E Mimetic Peptide Platform to Anji Pharma, China NATICK, Mass., May 07, 2018 -- LipimetiX Development, Inc. announced today that Anji Pharmaceuticals, Inc. has entered a licensing agreement for the LipimetiX platform of peptides for development of these drug candidates in commercial indications in mainland China, Taiwan and Hong Kong. Anji Pharma’s mission is to license and develop promising therapeutic technologies that address under-served markets in China. The Anji Pharma’s license provides exclusive rights to and use of the LipimetiX patent portfolio of Apo E mimetic peptides and formulations in the above-mentioned territory. Terms include an upfront licensing payment to LipimetiX of US$2.0 million, multiple additional cash payments up..."
02/01/2018 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "First Amendment to Securities Purchase Loan and Security Agreement dated January 30, 2018, by and between Capstone Therapeutics, Corp. and BP Peptides, LLC",
"Warrant to Purchase Common Stock"
08/14/2017 8-K Quarterly results
07/17/2017 8-K Form 8-K - Current report:
06/30/2017 8-K Form 8-K - Current report
06/15/2017 8-K Form 8-K - Current report
04/19/2017 8-K Form 8-K - Current report
03/18/2016 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/14/2013 8-K Quarterly results
Docs: "Capstone Therapeutics Will Provide an Operating Update and Announces Second Quarter 2013 Financial Results",
"Capstone Therapeutics Operating Update, August 14, 2013"
03/14/2013 8-K Quarterly results
Docs: "Capstone Therapeutics Will Provide an Operating Update and Announces 2012 Financial Results",
"Capstone Therapeutics Operating Update, March 14, 2013"
12/06/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "Apolipoprotein E Mimetic Peptide AEM-28 Granted Orphan Drug Designation for the Treatment of Homozygous Familial Hypercholesterolemia"
11/08/2012 8-K Quarterly results
Docs: "Capstone Therapeutics Will Provide an Operating Update and Announces Third Quarter 2012 Financial Results",
"Capstone Therapeutics Operating Update, November 8, 2012"
08/10/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/08/2012 8-K Investor presentation
Docs: "Presentation - Capstone Therapeutics Corp. Operating Update - August 8, 2012"
08/03/2012 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Fin...
Docs: "Capstone Therapeutics Enters Into a Joint Venture for the Development of Apo E Mimetic Peptide AEM-28 and Analogs and Announces Conference Call"
06/18/2012 8-K Form 8-K - Current report
01/20/2012 8-K Form 8-K - Current report
10/14/2011 8-K Form 8-K - Current report
08/23/2011 8-K Form 8-K - Current report
07/01/2011 8-K Submission of Matters to a Vote of Security Holders, Other Events
06/17/2011 8-K Form 8-K - Current report
06/08/2011 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Regulation FD Disclosure, F...
Docs: "Second Amendment to Rights Agreement, by and between Capstone Therapeutics Corp. and The Bank of New York",
"Capstone Therapeutics Announces Adjournment of Its Annual Meeting of Stockholders and Intention to Reconvene the Meeting on June 28, 2011"
06/06/2011 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Annual Meeting Update, June 6, 2011"
05/12/2011 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
05/09/2011 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
04/27/2011 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Capstone Therapeutics Confirms Early Signal of AZX100 Effect Based on Final Results of Phase 2a Pilot Clinical Trial in Surgical Scarring",
"Ca"
03/29/2011 8-K Form 8-K - Current report
12/14/2010 8-K Form 8-K - Current report
11/12/2010 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
11/10/2010 8-K Quarterly results
Docs: "Capstone Therapeutics Announces Third Quarter 2010 Financial Results Tempe, AZ – November 10, 2010 ─ Capstone Therapeutics ; formerly OrthoLogic Corp.; , today announced financial results for the third quarter of 2010. The Company reported a net loss of $2.6 million, or $0.06 per share, for the third quarter of 2010, compared to a net loss of $3.3 million or $0.08 per share for the third quarter of 2009. The Company incurred a net loss in the nine months ended September 30, 2010 of $8.5 million or $0.21 per share, compared to a net loss of $10.6 million or $0.26 per share in the same period in 2009. The $2.1 million decrease in the net loss for the nine months ended September 30, 2010 compared to the same period in 2009 resulted primarily from the purchase in 2009 of peptide for pre-..."
08/09/2010 8-K Form 8-K - Current report
05/25/2010 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Departure of Directors or C...
Docs: "Certificate of Amendment of Restated Certificate of Incorporation",
"First Amendment to Rights Agreement, by and between Capstone Therapeutics Corp. and The Bank of New York",
"Capstone Therapeutics Corp. Appoints Robert J. Spiegel, MD to Board of directors Tempe, AZ – May 24, 2010 ─ Capstone Therapeutics Corp. , , announced today the appointment of Robert J. Spiegel, MD to its Board of Directors. Dr. Spiegel has over 25 years of executive-level pharmaceutical development and product commercialization experience with Schering-Plough. Until his retirement in November 2009, Dr. Spiegel held the position of Chief Medical Officer at Schering-Plough and was a member of their Pharmaceutical Leadership Board and Corporate Licensing Review Board; he was also Chairman of Schering-Plough’s Safety Review Board and Preparedness Response Committee . While with Schering-Plough, Dr. Spiegel was involved in the filing of over thirty NDA submissions and interacted with US F..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy